The days of Roche having an immunotherapy monopoly on the largest population of small-cell lung cancer patients appear numbered, following the release of data for a competing drug.
{iframe}https://medcitynews.com/2019/06/astrazenecas-immunotherapy-drug-scores-key-phase-iii-lung-cancer-win/?rf=1&utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=74160846&_hsenc=p2ANqtz-8UKzKDGDoRT5QPnmEFyBb8JL2RYIABIi66IRpFDZSPdnNgO2N25kMZSwShXoU7dQLwqugbOU-MmtQIkSWscHzGtHjzag&_hsmi=74160846{/iframe}